Welgene Biotech Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 09, 2023
Share
Welgene Biotech Co.,Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 77.33 million compared to TWD 105.46 million a year ago. Net income was TWD 5.86 million compared to TWD 12.49 million a year ago. Basic earnings per share from continuing operations was TWD 0.25 compared to TWD 0.54 a year ago. Diluted earnings per share from continuing operations was TWD 0.25 compared to TWD 0.54 a year ago.
For the six months, sales was TWD 126.46 million compared to TWD 177.42 million a year ago. Net income was TWD 0.954 million compared to TWD 7.4 million a year ago. Basic earnings per share from continuing operations was TWD 0.04 compared to TWD 0.32 a year ago. Diluted earnings per share from continuing operations was TWD 0.04 compared to TWD 0.32 a year ago.
WELGENE BIOTECH CO., LTD. is a Taiwan-based company mainly engaged in the provision of genetic testing services and products. The company focuses on deoxyribonucleic acid (DNA) microarray, Next Generation Sequencing and real-time quantitative polymerase chain reaction (PCR) and other testing technologies, which used in school research units, hospitals and biotech companies. The Company is also engaged in the trading of medical equipment. The company mainly operates in two business segments, including Biotechnology Testing segment and Equipment Trading segment. The Company mainly operates in Taiwan market.